Preeclampsia Laboratory Testing Market Forecast 2024-2028

The preeclampsia laboratory testing market is projected to grow by USD 855.3 million from 2023 to 2028, registering a CAGR of 8.09%. The market's expansion is driven by increasing prevalence in emerging economies, rising demand for companion diagnostics, and technological advancements in testing methods. However, limited awareness and access to healthcare services in certain regions present challenges to adoption.

For more details about the industry, get the PDF sample report for free

Market Segmentation

By Product Type

• Consumables
• Instruments

By Test Type

• Blood Test
• Urine Test
• Others

By Region

• North America

  • US

• Europe

  • Germany
  • UK

• Asia

  • China
  • India

• Rest of the World (ROW)

Segment Insights

Consumables Segment

The consumables segment is anticipated to experience notable growth due to the frequent use of reagents and low costs associated with these products. The increasing reliance on online platforms for purchasing laboratory consumables is further driving demand.

Laboratories and hospitals depend on consumables for accurate preeclampsia diagnosis, with essential tests including blood pressure monitoring, liver and kidney function assessments, and biomarker analysis. Personalized medicinal products, point-of-care (POC) solutions, and novel technologies are key trends influencing the segment’s expansion.

Market Dynamics

Drivers

• Expansion in Emerging Economies

  • The market is growing in China, India, and Brazil, where preeclampsia prevalence is increasing due to lifestyle disorders and high-risk pregnancies.
  • Rising teenage pregnancy rates and the presence of infections like malaria and urinary tract infections (UTIs) contribute to demand for diagnostic solutions.

• Advancements in Disease Management

  • The adoption of biomarkers, precision medicine, and POC testing supports improved patient satisfaction and treatment adherence.
  • Health insurance policies and patient advocacy groups are playing a crucial role in raising awareness.

Trends

• Growing Need for Companion Diagnostics

  • Companion diagnostics provide personalized medical insights through in-vitro POC testing.
  • Increasing demand for biomarkers, personalized medicinal products, and early detection methods enhances market penetration.

• Technological Advancements

  • Blood pressure monitoring, liver and kidney function tests, and novel biomarker-based diagnostics are becoming essential in laboratory testing.
  • Calcium supplements and aspirin doses are frequently prescribed for preeclampsia management.

Challenges

• Limited Awareness and Healthcare Services in Developing Regions
  • Many developing countries lack adequate diagnostic infrastructure and affordable healthcare services.
  • Accessibility to advanced testing solutions remains a challenge in remote areas.

Get more details by ordering the complete report

Key Players

• Abbott Laboratories
• ACON Laboratories Inc.
• Avecon Healthcare Pvt. Ltd.
• Bio-Rad Laboratories Inc.
• BioCheck Inc.
• bioMérieux SA
• Biora Therapeutics Inc.
• Cardinal Health Inc.
• Diabetomics Inc.
• F. Hoffmann-La Roche Ltd.
• GestVision Inc.
• Lifeassay Diagnostics Pty Ltd.
• MedGyn Products Inc.
• Metabolomic Diagnostics
• MOMM Diagnostics
• PerkinElmer Inc.
• QuidelOrtho Corp.
• Sera Prognostics Inc.
• Siemens AG
• Thermo Fisher Scientific Inc.

Future Insights

The market is set to grow with increasing demand for early detection, precision diagnostics, and improved accessibility to testing solutions. As awareness continues to rise and healthcare infrastructure expands, the preeclampsia laboratory testing industry is expected to witness substantial advancements in technology and adoption rates.